S. S. Fandos

Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

Y. Drew, R. Plummer, N. Tunariu, 2016 .

A study of motivations and expectations of patients seen in phase 1 oncology clinics

Juanita Lopez, U. Banerji, S. Kaye, 2016, Cancer.

Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients

R. Plummer, N. Tunariu, Juanita Lopez, 2015 .

Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

N. Tunariu, Juanita Lopez, U. Banerji, 2017 .